Recombinant Human IFNB1 protein, GST-tagged

• Cat.No.: IFNB1-3074H
• Product Overview: Recombinant Human IFNB1 protein(P01574)(22-187aa), fused to N-terminal GST tag, was expressed in E. coli.

Specification

• Source: E. coli
• Species: Human
• Tag: GST
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
  If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 47 kDa
• Protein length: 22-187aa
• AA Sequence: MSYNLLGFLQRSSNFQCQKLLWQLN GRLEYCLKDRMNFDIPEEIKQLQQF QKEDAALTIYEMLQNIFAIFRQDSS STGWNETIVENLLANVYHQINHLKT VLEEKLEKEDFTRGKLMSSLHLKRY YGRILHYLKAKEYSHCAWTIVRVEI LRNFYFINRLTGYLRN
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%.

Gene Information

• Gene Name: IFNB1 interferon, beta 1, fibroblast [ Homo sapiens ]
• Official Symbol: IFNB1
• Synonyms: IFNB1; interferon, beta 1, fibroblast; IFNB; interferon beta; IFB; IFF; IFN-beta; fibroblast interferon; MGC96956
• Gene ID: 3456
• mRNA Refseq: NM_002176
• Protein Refseq: NP_002167
• MIM: 147640
• UniProt ID: P01574

Reviews

06/24/2021

The manufacturer not only ensures the provision of superior protein but also aids researchers with their solid technical support, offering the necessary resources to optimize experimental protocols.

08/29/2020

the IFNB1 protein offers numerous advantages for researchers conducting trials due to its high quality and stability.

11/08/2018

manufacturers or suppliers of proteins can play a crucial role in supporting researchers during trials.

Q&As

Are there any contraindications for IFNB1 treatment?

IFNB1 is generally not recommended for individuals with a history of hypersensitivity to interferons or other components of the drug. It should be used with caution in patients with certain pre-existing medical conditions.

Can IFNB1 be used in cancer treatment?

IFNB1 is being investigated for its potential role in cancer treatment due to its immunomodulatory effects. Clinical trials are ongoing to evaluate its efficacy in various types of cancer.

What are the potential side effects of IFNB1 treatment?

Common side effects include flu-like symptoms, injection site reactions, and changes in blood cell counts. Serious side effects are rare but can include liver problems and allergic reactions.

How is IFNB1 administered in clinical settings?

IFNB1 is often administered through subcutaneous or intramuscular injections. The frequency and dosage depend on the specific condition being treated.

In what other conditions is IFNB1 protein clinically utilized?

IFNB1 is also used in the treatment of certain viral infections, such as hepatitis B and C. It has antiviral properties that can inhibit viral replication.